ZA200201228B - Single-stranded oligodeoxynucleotide mutational vectors. - Google Patents

Single-stranded oligodeoxynucleotide mutational vectors. Download PDF

Info

Publication number: ZA200201228B
Authority: ZA; South Africa
Prior art keywords: ssomv; cell; deoxynucleotides; nucleotide; cells
Prior art date: 1999-08-27

Application number

ZA200201228A

Other languages

English (en)

Inventor

Richard A Metz

Bruce L Frank

Debra M Walther

Original Assignee

Valigen Us Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-08-27

Filing date

2002-02-13

Publication date

2003-05-28

2002-02-13 Application filed by Valigen Us Inc filed Critical Valigen Us Inc

2003-05-28 Publication of ZA200201228B publication Critical patent/ZA200201228B/en

Links

229940046166 oligodeoxynucleotide Drugs 0.000 title claims abstract description 36
239000013598 vector Substances 0.000 title description 30
230000000869 mutational effect Effects 0.000 title description 26
210000004027 cell Anatomy 0.000 claims abstract description 70
125000003729 nucleotide group Chemical group 0.000 claims abstract description 50
108090000623 proteins and genes Proteins 0.000 claims abstract description 47
230000002068 genetic effect Effects 0.000 claims abstract description 23
230000008859 change Effects 0.000 claims abstract description 18
108091034117 Oligonucleotide Proteins 0.000 claims abstract description 14
239000000203 mixture Substances 0.000 claims abstract description 14
239000002773 nucleotide Substances 0.000 claims description 49
238000000034 method Methods 0.000 claims description 12
150000002632 lipids Chemical class 0.000 claims description 11
230000002759 chromosomal effect Effects 0.000 claims description 8
210000004102 animal cell Anatomy 0.000 claims description 7
239000001963 growth medium Substances 0.000 claims description 6
239000003446 ligand Substances 0.000 claims description 6
238000004519 manufacturing process Methods 0.000 claims description 3
239000002077 nanosphere Substances 0.000 claims description 3
150000003839 salts Chemical class 0.000 claims description 3
241000124008 Mammalia Species 0.000 claims 2
239000003937 drug carrier Substances 0.000 claims 1
230000001580 bacterial effect Effects 0.000 abstract description 15
230000004048 modification Effects 0.000 abstract description 15
238000012986 modification Methods 0.000 abstract description 15
241000894006 Bacteria Species 0.000 abstract description 11
210000004962 mammalian cell Anatomy 0.000 abstract description 7
241001465754 Metazoa Species 0.000 abstract description 5
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract description 3
238000001727 in vivo Methods 0.000 abstract description 2
108091028664 Ribonucleotide Proteins 0.000 abstract 1
210000003494 hepatocyte Anatomy 0.000 abstract 1
239000002336 ribonucleotide Substances 0.000 abstract 1
125000001424 substituent group Chemical group 0.000 description 15
239000003471 mutagenic agent Substances 0.000 description 14
230000035772 mutation Effects 0.000 description 14
239000000975 dye Substances 0.000 description 13
241000196324 Embryophyta Species 0.000 description 12
230000000903 blocking effect Effects 0.000 description 12
238000006243 chemical reaction Methods 0.000 description 11
238000001890 transfection Methods 0.000 description 11
210000004436 artificial bacterial chromosome Anatomy 0.000 description 9
102000005962 receptors Human genes 0.000 description 9
108020003175 receptors Proteins 0.000 description 9
229960000318 kanamycin Drugs 0.000 description 8
201000010099 disease Diseases 0.000 description 7
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
229930027917 kanamycin Natural products 0.000 description 7
SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 7
229930182823 kanamycin A Natural products 0.000 description 7
230000001681 protective effect Effects 0.000 description 7
241000271566 Aves Species 0.000 description 6
YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 6
229920002873 Polyethylenimine Polymers 0.000 description 6
OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 6
239000012634 fragment Substances 0.000 description 6
108020004705 Codon Proteins 0.000 description 5
239000000969 carrier Substances 0.000 description 5
235000019152 folic acid Nutrition 0.000 description 5
239000011724 folic acid Substances 0.000 description 5
150000004713 phosphodiesters Chemical class 0.000 description 5
102000005427 Asialoglycoprotein Receptor Human genes 0.000 description 4
108020004414 DNA Proteins 0.000 description 4
241000700159 Rattus Species 0.000 description 4
230000000692 anti-sense effect Effects 0.000 description 4
108010006523 asialoglycoprotein receptor Proteins 0.000 description 4
229960005091 chloramphenicol Drugs 0.000 description 4
230000000295 complement effect Effects 0.000 description 4
238000011161 development Methods 0.000 description 4
229940014144 folate Drugs 0.000 description 4
239000004009 herbicide Substances 0.000 description 4
230000037361 pathway Effects 0.000 description 4
238000006467 substitution reaction Methods 0.000 description 4
102000005853 Clathrin Human genes 0.000 description 3
108010019874 Clathrin Proteins 0.000 description 3
PHEDXBVPIONUQT-UHFFFAOYSA-N Cocarcinogen A1 Natural products CCCCCCCCCCCCCC(=O)OC1C(C)C2(O)C3C=C(C)C(=O)C3(O)CC(CO)=CC2C2C1(OC(C)=O)C2(C)C PHEDXBVPIONUQT-UHFFFAOYSA-N 0.000 description 3
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 3
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
LEBBDRXHHNYZIA-LDUWYPJVSA-N [(2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] n-[(z)-1,3-dihydroxyoctadec-4-en-2-yl]carbamate Chemical compound CCCCCCCCCCCCC\C=C/C(O)C(CO)NC(=O)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O LEBBDRXHHNYZIA-LDUWYPJVSA-N 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
239000003153 chemical reaction reagent Substances 0.000 description 3
WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 3
229930193282 clathrin Natural products 0.000 description 3
OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical class NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
XDDAORKBJWWYJS-UHFFFAOYSA-N glyphosate Chemical compound OC(=O)CNCP(O)(O)=O XDDAORKBJWWYJS-UHFFFAOYSA-N 0.000 description 3
PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 3
PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 description 3
239000013612 plasmid Substances 0.000 description 3
108091033319 polynucleotide Proteins 0.000 description 3
102000040430 polynucleotide Human genes 0.000 description 3
239000002157 polynucleotide Substances 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 3
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
WTBFLCSPLLEDEM-JIDRGYQWSA-N 1,2-dioleoyl-sn-glycero-3-phospho-L-serine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCC\C=C/CCCCCCCC WTBFLCSPLLEDEM-JIDRGYQWSA-N 0.000 description 2
SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 description 2
CKTSBUTUHBMZGZ-SHYZEUOFSA-N 2'‐deoxycytidine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 CKTSBUTUHBMZGZ-SHYZEUOFSA-N 0.000 description 2
241000251468 Actinopterygii Species 0.000 description 2
BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
102000000844 Cell Surface Receptors Human genes 0.000 description 2
108010001857 Cell Surface Receptors Proteins 0.000 description 2
CKTSBUTUHBMZGZ-UHFFFAOYSA-N Deoxycytidine Natural products O=C1N=C(N)C=CN1C1OC(CO)C(O)C1 CKTSBUTUHBMZGZ-UHFFFAOYSA-N 0.000 description 2
241000588724 Escherichia coli Species 0.000 description 2
108010092364 Glucuronosyltransferase Proteins 0.000 description 2
239000005562 Glyphosate Substances 0.000 description 2
241000238631 Hexapoda Species 0.000 description 2
239000012124 Opti-MEM Substances 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
102000001218 Rec A Recombinases Human genes 0.000 description 2
108010055016 Rec A Recombinases Proteins 0.000 description 2
240000004808 Saccharomyces cerevisiae Species 0.000 description 2
108091081021 Sense strand Proteins 0.000 description 2
238000012300 Sequence Analysis Methods 0.000 description 2
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
108060008724 Tyrosinase Proteins 0.000 description 2
150000001412 amines Chemical class 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
230000003115 biocidal effect Effects 0.000 description 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
239000000470 constituent Substances 0.000 description 2
239000005547 deoxyribonucleotide Substances 0.000 description 2
125000002637 deoxyribonucleotide group Chemical group 0.000 description 2
230000000694 effects Effects 0.000 description 2
238000004520 electroporation Methods 0.000 description 2
239000012091 fetal bovine serum Substances 0.000 description 2
108020005243 folate receptor Proteins 0.000 description 2
102000006815 folate receptor Human genes 0.000 description 2
239000008103 glucose Substances 0.000 description 2
229940097068 glyphosate Drugs 0.000 description 2
230000002363 herbicidal effect Effects 0.000 description 2
230000006801 homologous recombination Effects 0.000 description 2
238000002744 homologous recombination Methods 0.000 description 2
238000003780 insertion Methods 0.000 description 2
230000037431 insertion Effects 0.000 description 2
238000009830 intercalation Methods 0.000 description 2
239000002502 liposome Substances 0.000 description 2
239000002609 medium Substances 0.000 description 2
239000012528 membrane Substances 0.000 description 2
150000007523 nucleic acids Chemical group 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
239000007790 solid phase Substances 0.000 description 2
241000894007 species Species 0.000 description 2
CABMTIJINOIHOD-UHFFFAOYSA-N 2-[4-methyl-5-oxo-4-(propan-2-yl)-4,5-dihydro-1H-imidazol-2-yl]quinoline-3-carboxylic acid Chemical compound N1C(=O)C(C(C)C)(C)N=C1C1=NC2=CC=CC=C2C=C1C(O)=O CABMTIJINOIHOD-UHFFFAOYSA-N 0.000 description 1
125000001731 2-cyanoethyl group Chemical group [H]C([H])(*)C([H])([H])C#N 0.000 description 1
FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
ZXICIFDEGMIMJY-UHFFFAOYSA-N 4-[2-[3-[3,3-dimethyl-1-(4-sulfobutyl)indol-2-ylidene]prop-1-enyl]-3,3-dimethylindol-1-ium-1-yl]butane-1-sulfonate Chemical class OS(=O)(=O)CCCCN1C2=CC=CC=C2C(C)(C)\C1=C\C=C\C1=[N+](CCCCS([O-])(=O)=O)C2=CC=CC=C2C1(C)C ZXICIFDEGMIMJY-UHFFFAOYSA-N 0.000 description 1
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
CKTSBUTUHBMZGZ-ULQXZJNLSA-N 4-amino-1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-tritiopyrimidin-2-one Chemical compound O=C1N=C(N)C([3H])=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 CKTSBUTUHBMZGZ-ULQXZJNLSA-N 0.000 description 1
108010000700 Acetolactate synthase Proteins 0.000 description 1
108700028369 Alleles Proteins 0.000 description 1
101710081722 Antitrypsin Proteins 0.000 description 1
240000003291 Armoracia rusticana Species 0.000 description 1
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
108091026890 Coding region Proteins 0.000 description 1
108091033380 Coding strand Proteins 0.000 description 1
108010079245 Cystic Fibrosis Transmembrane Conductance Regulator Proteins 0.000 description 1
102000053602 DNA Human genes 0.000 description 1
230000033616 DNA repair Effects 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
102000001301 EGF receptor Human genes 0.000 description 1
108060006698 EGF receptor Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
208000031220 Hemophilia Diseases 0.000 description 1
208000009292 Hemophilia A Diseases 0.000 description 1
239000005981 Imazaquin Substances 0.000 description 1
208000026350 Inborn Genetic disease Diseases 0.000 description 1
241001529936 Murinae Species 0.000 description 1
OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
241000244206 Nematoda Species 0.000 description 1
108091028043 Nucleic acid sequence Proteins 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
241000589516 Pseudomonas Species 0.000 description 1
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
239000012979 RPMI medium Substances 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
241000607142 Salmonella Species 0.000 description 1
108020004682 Single-Stranded DNA Proteins 0.000 description 1
229940100389 Sulfonylurea Drugs 0.000 description 1
108090000992 Transferases Proteins 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
102000003425 Tyrosinase Human genes 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
230000001464 adherent effect Effects 0.000 description 1
238000013019 agitation Methods 0.000 description 1
230000004075 alteration Effects 0.000 description 1
230000001475 anti-trypsic effect Effects 0.000 description 1
238000003556 assay Methods 0.000 description 1
230000002238 attenuated effect Effects 0.000 description 1
210000003578 bacterial chromosome Anatomy 0.000 description 1
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
229960002685 biotin Drugs 0.000 description 1
235000020958 biotin Nutrition 0.000 description 1
239000011616 biotin Substances 0.000 description 1
125000002091 cationic group Chemical group 0.000 description 1
235000012000 cholesterol Nutrition 0.000 description 1
239000013599 cloning vector Substances 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
238000010276 construction Methods 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
244000038559 crop plants Species 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
238000010790 dilution Methods 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
238000005538 encapsulation Methods 0.000 description 1
238000001125 extrusion Methods 0.000 description 1
239000007850 fluorescent dye Substances 0.000 description 1
229960000304 folic acid Drugs 0.000 description 1
150000002224 folic acids Chemical class 0.000 description 1
239000012737 fresh medium Substances 0.000 description 1
238000012239 gene modification Methods 0.000 description 1
230000004077 genetic alteration Effects 0.000 description 1
231100000118 genetic alteration Toxicity 0.000 description 1
208000016361 genetic disease Diseases 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
230000005017 genetic modification Effects 0.000 description 1
235000013617 genetically modified food Nutrition 0.000 description 1
206010073071 hepatocellular carcinoma Diseases 0.000 description 1
231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
238000009396 hybridization Methods 0.000 description 1
MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
125000001041 indolyl group Chemical group 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
230000003902 lesion Effects 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
210000002752 melanocyte Anatomy 0.000 description 1
238000001471 micro-filtration Methods 0.000 description 1
238000000386 microscopy Methods 0.000 description 1
238000007479 molecular analysis Methods 0.000 description 1
FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
231100000956 nontoxicity Toxicity 0.000 description 1
108020004707 nucleic acids Proteins 0.000 description 1
102000039446 nucleic acids Human genes 0.000 description 1
210000004940 nucleus Anatomy 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
239000002953 phosphate buffered saline Substances 0.000 description 1
125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
150000008300 phosphoramidites Chemical class 0.000 description 1
230000019612 pigmentation Effects 0.000 description 1
229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
239000013641 positive control Substances 0.000 description 1
210000001236 prokaryotic cell Anatomy 0.000 description 1
125000006239 protecting group Chemical group 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
150000003230 pyrimidines Chemical class 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000008439 repair process Effects 0.000 description 1
230000003362 replicative effect Effects 0.000 description 1
125000002652 ribonucleotide group Chemical group 0.000 description 1
239000012064 sodium phosphate buffer Substances 0.000 description 1
239000000243 solution Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical compound OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 1
230000002195 synergetic effect Effects 0.000 description 1
125000003698 tetramethyl group Chemical group [H]C([H])([H])* 0.000 description 1
229940104230 thymidine Drugs 0.000 description 1
239000002753 trypsin inhibitor Substances 0.000 description 1
229960005486 vaccine Drugs 0.000 description 1
230000035899 viability Effects 0.000 description 1
238000003260 vortexing Methods 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
238000005303 weighing Methods 0.000 description 1
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
Biomedical Technology (AREA)
Wood Science & Technology (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Crystallography & Structural Chemistry (AREA)
Physics & Mathematics (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Molecular Biology (AREA)
Plant Pathology (AREA)
Microbiology (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Gastroenterology & Hepatology (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Medicinal Preparation (AREA)
Breeding Of Plants And Reproduction By Means Of Culturing (AREA)

ZA200201228A 1999-08-27 2002-02-13 Single-stranded oligodeoxynucleotide mutational vectors. ZA200201228B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US09/384,960 US6271360B1 (en)	1999-08-27	1999-08-27	Single-stranded oligodeoxynucleotide mutational vectors

Publications (1)

Publication Number	Publication Date
ZA200201228B true ZA200201228B (en)	2003-05-28

Family

ID=23519459

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200201228A ZA200201228B (en)	1999-08-27	2002-02-13	Single-stranded oligodeoxynucleotide mutational vectors.

Country Status (15)

Country	Link
US (3)	US6271360B1 (de)
EP (3)	EP1210123B1 (de)
JP (2)	JP5697187B2 (de)
CN (1)	CN1384759B (de)
AT (1)	ATE478687T1 (de)
AU (2)	AU773242C (de)
BR (1)	BR0013590A (de)
CA (1)	CA2382120C (de)
DE (1)	DE60044876D1 (de)
DK (3)	DK2266627T3 (de)
ES (3)	ES2544727T3 (de)
NZ (1)	NZ517942A (de)
PT (3)	PT2324856E (de)
WO (1)	WO2001015740A1 (de)
ZA (1)	ZA200201228B (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6652607B2 (en)	1999-07-07	2003-11-25	The Lubrizol Corporation	Concentrated emulsion for making an aqueous hydrocarbon fuel
EP1212406A1 (de) *	1999-08-20	2002-06-12	University Of Delaware	Zellfreies testverfahren für zielgerichtete genveränderungen und konversionen von pflanzengenen
US6271360B1 (en) *	1999-08-27	2001-08-07	Valigen (Us), Inc.	Single-stranded oligodeoxynucleotide mutational vectors
AR025996A1 (es)	1999-10-07	2002-12-26	Valigen Us Inc	Plantas no transgenicas resistentes a los herbicidas.
NZ521698A (en) *	2000-03-27	2004-08-27	Univ Delaware	Targeted chromosomal genomic alterations with modified single stranded oligonucleotides
US6936467B2 (en) *	2000-03-27	2005-08-30	University Of Delaware	Targeted chromosomal genomic alterations with modified single stranded oligonucleotides
EP1284985A2 (de) *	2000-05-17	2003-02-26	University Of Delaware	Dns-olinucleotide für zielgerichtete veränderung von pflanzengenen
WO2002010364A2 (en) *	2000-07-27	2002-02-07	University Of Delaware	Methods for enhancing targeted gene alteration using oligonucleotides
US7053195B1 (en) *	2001-06-12	2006-05-30	Syngenta Participatious Ag	Locked nucleic acid containing heteropolymers and related methods
CA2455424A1 (en) *	2001-08-07	2003-02-20	University Of Delaware	Compositions and methods for the prevention and treatment of huntington's disease
US20040096880A1 (en) *	2001-08-07	2004-05-20	Kmiec Eric B.	Compositions and methods for the treatment of diseases exhibiting protein misassembly and aggregation
US7112405B2 (en) *	2001-09-27	2006-09-26	University Of Delaware	Compositions and methods for enhancing oligonucleotide-mediated gene alteration
EP1448766A2 (de) *	2001-09-27	2004-08-25	University Of Delaware	Coisogene eukaryontische zellansammlungen
AU2003220119A1 (en) *	2002-03-07	2003-09-22	University Of Delaware	Methods, compositions, and kits for enhancing oligonucleotide-mediated nucleic acid sequence alteration using compositions comprising a histone deacetylase inhibitor, lambda phage beta protein, or hydroxyurea
GB0218803D0 (en) *	2002-08-13	2002-09-18	Nl Kanker I	Targeted gene modification by single-standed DNA oligonucleotides
US20040175722A1 (en) *	2002-10-07	2004-09-09	Kmiec Eric B.	Methods and compositions for reducing screening in oligonucleotide-directed nucleic acid sequence alteration
US6929917B2 (en) *	2002-11-18	2005-08-16	Pregentis	Method for cloning of a rare, specifically mutated cell
US20070072815A1 (en) *	2004-05-04	2007-03-29	Kmiec Eric B	Methods and kits to increase the efficiency of oligonucleotide-directed nucleic acid sequence alteration
UA99594C2 (en)	2006-01-12	2012-09-10	Сайбас Юроп Б.В.	Epsps mutants
US8029579B2 (en)	2006-06-28	2011-10-04	COH Inc.	Fatty acid blends and uses therefor
PL2177605T3 (pl)	2006-10-06	2015-05-29	Basf Plant Science Gmbh	Delta-5 desaturazy i sposób wytwarzania wielokrotnie nienasyconych kwasów tłuszczowych w organizmach transgenicznych innych niż człowiek
US9102948B2 (en)	2006-11-17	2015-08-11	22Nd Century Limited, Llc	Regulating alkaloids
PL2700721T3 (pl) *	2007-10-05	2019-06-28	Cibus Europe B.V.	Zmutowane geny kodujące syntazę kwasu acetohydroksylowego w brassica
DK2234994T3 (da) *	2007-12-27	2017-11-13	Cibus Europe Bv	Fedtsyre-butylester-blandinger
AU2009248852B9 (en)	2008-05-23	2015-08-13	Cibus Europe B.V.	Production of squalene using yeast
CN103834675A (zh)	2008-09-26	2014-06-04	巴斯夫农化产品有限公司	除草剂-抗性的ahas-突变体及使用方法
EP2669380B1 (de)	2008-12-12	2017-09-27	BASF Plant Science GmbH	Desaturasen und Verfahren zur Herstellung von mehrfach ungesättigten Fettsäuren in transgenen Organismen
EP3219815B1 (de) *	2009-11-23	2019-10-02	Cibus Europe B.V.	Verfahren und zusammensetzungen zur herstellung von squalen mithilfe von hefe
UA112969C2 (uk)	2010-08-03	2016-11-25	Сібас Юс Ллс	Рослина, стійка до одного або більше ррх-інгібуючих гербіцидів, яка містить мутантний ген протопорфіриноген ix оксидази (ррх)
US20120122223A1 (en)	2010-08-03	2012-05-17	Cibus Us Llc	Mutated protoporphyrinogen ix oxidase (ppx) genes
WO2012028673A1 (en)	2010-09-02	2012-03-08	Ludwig-Maximilians-Universitaet Muenchen	Spontaneous organogenesis in plants
EP2426204A1 (de)	2010-09-02	2012-03-07	Ludwig-Maximilians-Universität München	Spontane Knöllchenorganogenese in Pflanzen
KR101137285B1 (ko)	2010-10-28	2012-04-20	위월드 주식회사	초소형 광대역 송수신 안테나 피더
CN104662156A (zh)	2012-08-17	2015-05-27	美国陶氏益农公司	玉米非翻译区域用于植物中转基因表达的用途
WO2014153178A2 (en)	2013-03-14	2014-09-25	Cibus Us Llc	Mutated allene oxide synthase 2 (aos2) genes
US9957515B2 (en)	2013-03-15	2018-05-01	Cibus Us Llc	Methods and compositions for targeted gene modification
LT3527068T (lt)	2013-03-15	2022-08-10	Cibus Us Llc	Būdai ir kompozicijos, skirti padidinti tikslinės geno modifikacijos efektyvumą, panaudojant geno reparaciją, kuriai tarpininkauja oligonukleotidas
US12331303B2 (en)	2013-03-15	2025-06-17	Cibus Us Llc	Methods and compositions for increasing efficiency of targeted gene modification using oligonucleotide-mediated gene repair
PL2966984T3 (pl)	2013-03-15	2022-06-13	Cibus Us Llc	Ukierunkowana modyfikacja genu z użyciem naprawy genu, w której pośredniczy oligonukleotyd
ES2974625T3 (es)	2014-03-14	2024-06-28	Cibus Us Llc	Procedimientos y composiciones para aumentar la eficacia de la modificación génica dirigida mediante reparación génica mediada por oligonucleótidos
KR102841205B1 (ko)	2016-02-09	2025-08-01	시버스 유에스 엘엘씨	올리고뉴클레오타이드 매개 유전자 보수를 사용한 표적화된 유전자 변형의 효율을 증가시키기 위한 방법 및 조성물
US10584363B2 (en)	2016-06-03	2020-03-10	Takara Bio Usa, Inc.	Methods of producing and using single-stranded deoxyribonucleic acids and compositions for use in practicing the same
CN111819285B (zh)	2018-01-09	2024-08-09	希博斯美国有限公司	防碎基因和突变
AU2019247403B2 (en)	2018-04-04	2025-04-10	Cibus Europe, B.V.	FAD2 genes and mutations

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2731844B2 (ja) *	1987-04-22	1998-03-25	ザ・ユニヴァーシティー・オブ・コネチカット	哺乳動物の細胞にポリヌクレオチドを導入するキャリア及び水溶性高分子複合体並びにその導入方法
ES2099718T3 (es) *	1990-07-02	1997-06-01	Hoechst Ag	Analogos de oligonucleotidos con uniones internucleotidicas de 3'-3' o 5'-5' terminales.
AU681997B2 (en)	1991-09-05	1997-09-18	University Of Connecticut, The	Targeted delivery of poly- or oligonucleotides to cells
US5808044A (en) *	1993-01-22	1998-09-15	Pharmacia Biotech Inc.	Indocarbocyanine and benzindocarbocyanine phosphoramidites
US5556959A (en)	1993-01-22	1996-09-17	Pharmacia P-L Biochemicals Inc.	Indocarbocyanine-linked phosphoramidites
CN1048254C (zh)	1993-12-09	2000-01-12	托马斯杰弗逊大学	用于将预定的改变引入靶基因中的化合物
US5780296A (en)	1995-01-17	1998-07-14	Thomas Jefferson University	Compositions and methods to promote homologous recombination in eukaryotic cells and organisms
WO1996040271A1 (en) *	1995-06-07	1996-12-19	Yale University	Treatment of hemoglobinopathies
US5908777A (en) *	1995-06-23	1999-06-01	University Of Pittsburgh	Lipidic vector for nucleic acid delivery
FR2736926B1 (fr)	1995-07-19	1997-08-22	Rhone Poulenc Agrochimie	5-enol pyruvylshikimate-3-phosphate synthase mutee, gene codant pour cette proteine et plantes transformees contenant ce gene
US5888983A (en)	1996-05-01	1999-03-30	Thomas Jefferson University	Method and oligonucleobase compounds for curing diseases caused by mutations
US5731181A (en)	1996-06-17	1998-03-24	Thomas Jefferson University	Chimeric mutational vectors having non-natural nucleotides
US5760012A (en)	1996-05-01	1998-06-02	Thomas Jefferson University	Methods and compounds for curing diseases caused by mutations
NZ337445A (en) *	1997-02-26	2000-12-22	Gen Hospital Corp	Transgenic animals and cell lines for screening drugs effective for the treatment or prevention of alzheimer's disease
NZ500694A (en)	1997-04-30	2001-09-28	Univ Minnesota	Use of chimeric mutational vector (CMV), a macromolecule and a ligand for cell surface receptor adhesion molecule (clatherin) in gene therapy; the CMV vector derived from REC2 homologous pairing with Ustilago maydis
US6524613B1 (en)	1997-04-30	2003-02-25	Regents Of The University Of Minnesota	Hepatocellular chimeraplasty
GB9711015D0 (en)	1997-05-28	1997-07-23	Zeneca Ltd	Improvements in or relating to organic compounds
US5986086A (en) *	1997-06-20	1999-11-16	Amersham Pharmacia Biotech Inc.	Non-sulfonated cyanine dyes for labeling nucleosides and nucleotides
EP1007712A4 (de)	1997-08-05	2004-06-30	Kimeragen Inc	Verwendung von duplex-oligonukleotiden zur beeinflussung lokaler genetischer veränderungen in pflanzen
EP1032692A1 (de)	1997-11-18	2000-09-06	Pioneer Hi-Bred International, Inc.	Gezielte manipulierung von herbizid-resistanz-gene in planzen
US6004804A (en)	1998-05-12	1999-12-21	Kimeragen, Inc.	Non-chimeric mutational vectors
US6271360B1 (en) *	1999-08-27	2001-08-07	Valigen (Us), Inc.	Single-stranded oligodeoxynucleotide mutational vectors
KR20170047291A (ko)	2014-08-21	2017-05-04	코닝 인코포레이티드	적층 유리 제품에서 기포를 방지하는 방법 및 이로부터 형성된 적층 유리 제품

1999
- 1999-08-27 US US09/384,960 patent/US6271360B1/en not_active Expired - Lifetime
2000
- 2000-08-25 PT PT101839603T patent/PT2324856E/pt unknown
- 2000-08-25 ES ES10183960.3T patent/ES2544727T3/es not_active Expired - Lifetime
- 2000-08-25 EP EP00959442A patent/EP1210123B1/de not_active Expired - Lifetime
- 2000-08-25 DK DK10008602.4T patent/DK2266627T3/da active
- 2000-08-25 ES ES10008602.4T patent/ES2542530T3/es not_active Expired - Lifetime
- 2000-08-25 EP EP20100008602 patent/EP2266627B1/de not_active Expired - Lifetime
- 2000-08-25 AT AT00959442T patent/ATE478687T1/de active
- 2000-08-25 CN CN008149968A patent/CN1384759B/zh not_active Expired - Lifetime
- 2000-08-25 WO PCT/US2000/023457 patent/WO2001015740A1/en not_active Ceased
- 2000-08-25 ES ES00959442T patent/ES2358292T3/es not_active Expired - Lifetime
- 2000-08-25 PT PT00959442T patent/PT1210123E/pt unknown
- 2000-08-25 PT PT100086024T patent/PT2266627E/pt unknown
- 2000-08-25 NZ NZ517942A patent/NZ517942A/en not_active IP Right Cessation
- 2000-08-25 AU AU70767/00A patent/AU773242C/en not_active Expired
- 2000-08-25 CA CA2382120A patent/CA2382120C/en not_active Expired - Lifetime
- 2000-08-25 DE DE60044876T patent/DE60044876D1/de not_active Expired - Lifetime
- 2000-08-25 DK DK10183960.3T patent/DK2324856T3/en active
- 2000-08-25 BR BR0013590-9A patent/BR0013590A/pt not_active Application Discontinuation
- 2000-08-25 DK DK00959442.5T patent/DK1210123T3/da active
- 2000-08-25 EP EP20100183960 patent/EP2324856B1/de not_active Expired - Lifetime
- 2000-08-25 US US09/645,889 patent/US6479292B1/en not_active Expired - Lifetime
- 2000-08-25 JP JP2001520151A patent/JP5697187B2/ja not_active Expired - Lifetime
2002
- 2002-02-13 ZA ZA200201228A patent/ZA200201228B/en unknown
- 2002-11-12 US US10/292,856 patent/US7060500B2/en not_active Expired - Lifetime
2004
- 2004-08-19 AU AU2004205139A patent/AU2004205139B2/en not_active Expired
2012
- 2012-05-10 JP JP2012108528A patent/JP5813571B2/ja not_active Expired - Lifetime

Also Published As

Publication number	Publication date
JP2003508451A (ja)	2003-03-04
EP2324856A1 (de)	2011-05-25
ATE478687T1 (de)	2010-09-15
AU7076700A (en)	2001-03-26
ES2544727T3 (es)	2015-09-03
US6479292B1 (en)	2002-11-12
AU2004205139A1 (en)	2004-09-16
CN1384759B (zh)	2013-05-22
EP1210123A4 (de)	2004-08-18
US20040023392A1 (en)	2004-02-05
PT1210123E (pt)	2010-11-30
NZ517942A (en)	2004-07-30
EP2266627A1 (de)	2010-12-29
AU2004205139B2 (en)	2008-01-10
CA2382120A1 (en)	2001-03-08
JP2012184246A (ja)	2012-09-27
JP5813571B2 (ja)	2015-11-17
EP1210123B1 (de)	2010-08-25
EP2266627B1 (de)	2015-04-22
ES2542530T3 (es)	2015-08-06
DK2324856T3 (en)	2015-08-03
DK1210123T3 (da)	2010-12-20
AU773242C (en)	2005-04-07
PT2324856E (pt)	2015-09-03
EP2324856B1 (de)	2015-05-06
AU773242B2 (en)	2004-05-20
PT2266627E (pt)	2015-08-25
US6271360B1 (en)	2001-08-07
DK2266627T3 (da)	2015-06-15
BR0013590A (pt)	2002-05-07
US7060500B2 (en)	2006-06-13
ES2358292T3 (es)	2011-05-09
CA2382120C (en)	2013-10-29
DE60044876D1 (de)	2010-10-07
WO2001015740A1 (en)	2001-03-08
JP5697187B2 (ja)	2015-04-08
EP1210123A1 (de)	2002-06-05
CN1384759A (zh)	2002-12-11

Publication	Publication Date	Title
AU773242C (en)	2005-04-07	Genetic alteration in plants using single-stranded oligonucleotide vectors
AU740336B2 (en)	2001-11-01	Heteroduplex mutational vectors and use thereof in bacteria
NZ278490A (en)	1998-03-25	Chimeric polynucleotide with both ribo- and deoxyribonucleotides in one strand and deoxyribonucleotides in a second strand
CA2404780A1 (en)	2001-10-04	Targeted chromosomal genomic alterations with modified single stranded oligonucleotides
EP1013770A1 (de)	2000-06-28	Nicht-viraler Transfektionsvektor
AU758406B2 (en)	2003-03-20	Vectors for transferring nucleic acids, compositions containing them and their uses
CN100540664C (zh)	2009-09-16	将突变转移到靶核酸中的方法